Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche China R&D Center Chief Scientific Officer Li Chen On Being a Pioneer in China (An Interview, Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Chen discusses how Roche is approaching R&D differently in China and the role that China will play in the global pharmaceutical arena.

You may also be interested in...



Roche China R&D Center Chief Scientific Officer Li Chen On Being a Pioneer in China: An Interview With PharmAsia News (Part 1 of 2)

Swiss-headquartered Roche, the first multinational pharmaceutical outfit to establish a research and development center in China, recently established one of its Pharma Partnering groups in Shanghai. Roche's China CSO Li Chen sat down with PharmAsia News recently to talk about how the company is approaching R&D in the region and evolving in tandem with the pharmaceutical landscape in China. Chen is also a member of the networking organization BayHelix, which links Chinese life sciences executives.

Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams On Seeking More Innovation In China And Korea: An Interview With PharmAsia News (Part 2 of 2)

Roche recently expanded its investment in innovation in Asia by opening its fourth Global Partnering office in Shanghai. Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams sat down with PharmAsia News' Shanghai Bureau to talk about the mission of the newly established partnering site and Roche's partnering strategies in Asia.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel